KZRKezar Life Sciences Inc
KZR
Kezar Life Sciences Inc1,732
Mkt Cap
$54.55MVolume
53,420.0052W High
$7.5552W Low
$3.53PE Ratio
-0.97KZR Fundamentals
Price
$7.40Prev Close
$7.40Open
$7.3650D MA
$6.61Beta
0.97Avg. Volume
79,679.45EPS (Annual)
-$7.66P/B
0.77Rev/Employee
$0.00$23.53
Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders?
Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders? Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 31, 2026 Insiders may stand to...
PR Newswire·5d ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar...
PR Newswire·6d ago
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Kezar Life...
PR Newswire·6d ago
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Kezar Life Sciences, Inc. (NASDAQ: KZR) to Aurinia Pharmaceuticals Inc. for $6.955 in cash per share and one non-transferable contingent value right. Halper Sadeh encourages Kezar shareholders to click here to learn more...
Business Wire·6d ago
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it...
Business Wire·6d ago
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a...
Business Wire·24d ago
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for...
Business Wire·5mo ago
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2025
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two...
Business Wire·5mo ago
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive
Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.
<
1
2
...
>